BRCA1 and breast carcinoma: However, the breast cancer risk readouts for BRCAPRO only include familial risk from BRCA1/2 and therefore the reassurance of reducing risks to population levels after negative BRCA1/2 testing is inappropriate, [20] as is demonstrated by the far lower breast cancer risk predictions with BRCAPRO compared to Tyrer-Cuzick and BOADICEA.